Statistical Analysis of Cost-effectiveness Data

個数:
  • ポイントキャンペーン

Statistical Analysis of Cost-effectiveness Data

  • 提携先の海外書籍取次会社に在庫がございます。通常2週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • ≪洋書のご注文につきまして≫ 「海外取次在庫あり」および「国内仕入れ先からお取り寄せいたします」表示の商品でも、納期の目安期間内にお届けできないことがございます。あらかじめご了承ください。

  • 製本 Hardcover:ハードカバー版/ページ数 196 p.
  • 言語 ENG
  • 商品コード 9780470856260
  • DDC分類 658.1554015195

基本説明

An essential reference for biostatisticians and health economists engaged in cost-effectiveness analysis of health-care interventions,

Full Description


The statistical analysis of cost-effectiveness data is becoming increasingly important within health and medical research. Statistical Analysis of Cost-Effectiveness Data provides a practical book that synthesises the huge amount of research that has taken place in the area over the last two decades. Comprising an up-to-date overview of the statistical analysis of cost-effectiveness data, the book is supported by numerous worked examples from the author's own experience. It has been written in a style suitable for medical statisticians and health care professionals alike. Key features include:* an overview of statistical methods used in the analysis of cost-effectiveness data. * coverage of Bayesian methodology.* illustrated throughout by worked examples using real data.* suitability for health care professionals with limited statistical knowledge.* discussion of software used for data analysis. An essential reference for biostatisticians and health economists engaged in cost-effectiveness analysis of health-care interventions, both in academia and industry. Also of interest to graduate students of biostatistics, public health and economics.

Table of Contents

Preface                                            xi
1 Concepts 1 (10)
1.1 Introduction 1 (1)
1.2 Cost-effectiveness data and the 2 (3)
parameters of interest
1.3 The cost-effectiveness plane, the ICER 5 (3)
and INB
1.4 Outline 8 (3)
2 Parameter Estimation for Non-censored Data 11 (16)
2.1 Introduction 11 (1)
2.2 Cost 12 (8)
2.2.1 Sample means for estimating 12 (2)
incremental cost
2.2.2 Using multiple regression models 14 (1)
2.2.3 Transformation (and the 15 (2)
retransformation problem)
2.2.4 Generalized linear models 17 (1)
2.2.5 Two-part models for excess zeros 18 (1)
2.2.6 Cost prediction models 19 (1)
2.3 Effectiveness 20 (5)
2.3.1 Probability of surviving 21 (1)
2.3.2 Mean survival time 21 (1)
2.3.3 Mean quality-adjusted survival time 22 (2)
2.3.4 Mean quality-adjusted survival: 24 (1)
controlling for baseline utility
2.4 Summary 25 (2)
3 Parameter Estimation for Censored Data 27 (16)
3.1 Introduction 27 (1)
3.2 Mean Cost 28 (6)
3.2.1 Direct (Lin) method 29 (2)
3.2.2 Inverse-probability weighting 31 (3)
3.3 Effectiveness 34 (8)
3.3.1 Probability of surviving 34 (2)
3.3.2 Mean survival time 36 (3)
3.3.3 Mean quality-adjusted survival time 39 (3)
3.4 Summary 42 (1)
4 Cost-effectiveness Analysis 43 (24)
4.1 Introduction 43 (1)
4.2 Incremental cost-effectiveness ratio 44 (5)
4.3 Incremental net benefit 49 (2)
4.4 The cost-effectiveness acceptability curve 51 (3)
4.5 Using bootstrap methods 54 (3)
4.6 A Bayesian incremental net benefit 57 (3)
approach
4.7 Kinked thresholds 60 (4)
4.8 Summary 64 (3)
5 Cost-effectiveness Analysis: Examples 67 (26)
5.1 Introduction 67 (1)
5.2 The CADET-Hp trial 67 (5)
5.3 Symptomatic hormone-resistant prostate 72 (5)
cancer
5.4 The Canadian implantable defibrillator 77 (5)
study (CMS)
5.5 The EVALUATE trial 82 (4)
5.6 Bayesian approach applied to the UK PDS 86 (4)
study
5.7 Summary 90 (3)
6 Power and Sample Size Determination 93 (24)
6.1 Introduction 93 (1)
6.2 Approaches based on the 94 (9)
cost-effectiveness plane
6.2.1 Briggs and Gray 95 (3)
6.2.2 Willan and O'Brien 98 (3)
6.2.3 Gardiner et al. 101(2)
6.3 The classical approach based on net 103(3)
benefit
6.3.1 The method 103(2)
6.3.2 Example 105(1)
6.4 Bayesian take on the classical approach 106(2)
6.4.1 The Method 106(1)
6.4.2 Example 107(1)
6.5 The value of information approach 108(8)
6.5.1 The method 108(6)
6.5.2 Example 114(2)
6.6 Summary 116(1)
7 Covariate Adjustment and Sub-group Analysis 117(28)
7.1 Introduction 117(1)
7.2 Non-censored data 118(11)
7.2.1 Example, non-censored data 121(8)
7.3 Censored data 129(13)
7.3.1 Cost 131(1)
7.3.2 Quality-adjusted survival time 132(2)
7.3.3 Survival time 134(1)
7.3.4 The Canadian implantable 135(3)
defibrillator study (CIDS)
7.3.5 The evaluate trial 138(4)
7.4 Summary 142(3)
8 Multicenter and Multinational Trials 145(20)
8.1 Introduction 145(2)
8.2 Background to multinational 147(4)
cost-effectiveness
8.3 Fixed effect approaches 151(3)
8.3.1 Willke et al. 151(1)
8.3.2 Cook et al. 152(2)
8.4 Random effects approaches 154(10)
8.4.1 Aggregate level analysis: multicenter 154(2)
trials
8.4.2 Aggregate level analysis: 156(6)
multinational trials
8.4.3 Hierarchical modeling 162(2)
8.5 Summary 164(1)
9 Modeling Cost-effectiveness 165(18)
9.1 Introduction 165(1)
9.2 A general framework for modeling 166(1)
cost-effectiveness results
9.3 Case study: an economic appraisal of the 167(13)
goal study
9.3.1 The GOAL study 168(2)
9.3.2 Standard approach to estimating 170(1)
cost-effectiveness
9.3.3 An alternative approach to estimating 171(8)
cost-effectiveness
9.3.4 Comparing the two analyses of GOAL 179(1)
9.4 Summary 180(3)
References 183(10)
Author Index 193(2)
Subject Index 195(2)
Series List 197